≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Interstitial cystitis (chronic), drug-induced

Endpoint Browser PheWeb

INTERSTITIAL_CYSTIT_CHRONIC

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ATC codes for adverse effects of Drugs — ANY
  • Hospital discharge: ICD-10 — N30.1#

1 out of 7 registries used, show all original rules.

120

4. Check minimum number of events

None

120

5. Include endpoints

None

120

6. Filter based on genotype QC (FinnGen only)

118

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Extra metadata

Level in the ICD hierarchy
C
First used in FinnGen datafreeze
DF5

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded (not available in FinRegistry).

-FinnGen-

Key figures

All Female Male
Number of individuals 118 105 13
Unadjusted period prevalence (%) 0.03 0.04 0.01
Median age at first event (years) 50.13 49.94 51.65

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
120
Matched controls
1200
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
N30.1
ICD-10 Finland
Interstitial cystitis (chronic)
+∞
161.1
120
8
KCV04
NOMESCO Finland
Distension of bladder with fluid
507.6
85.7
76
*
UKC02
NOMESCO Finland
Cystoscopy
31.6
84.5
88
96
G04BD07
ATC
tolterodine; oral
17.5
49.7
50
47
G04BD04
ATC
oxybutynin; oral, transdermal
15.5
49.7
57
66
5951A
ICD-9 Finland
Cystitis, Chronic interstitial cystitis
+∞
34.0
31
*
7325
FHL
Bladder stretching
+∞
31.7
29
*
XKD00
NOMESCO Finland
Uroflowmetry
10.4
30.6
42
59
R35
ICD-10 Finland
Polyuria
8.4
21.4
33
52
59504
ICD-8 Finland
Cystitis, Interstitialis (Hunner)
237.6
20.2
20
*
1530
FHL
Urethrocystoscopy
46.8
19.4
23
6
TKD00
NOMESCO Finland
Dilatation of urethra
111.9
18.1
19
*
N30.0
ICD-10 Finland
Acute cystitis
4.7
15.3
51
162
J01MA06
ATC
norfloxacin; oral
4.8
15.1
49
152
ZX136
NOMESCO Finland
Intravesicalis
91.6
15.0
16
*
J01EA01
ATC
trimethoprim; systemic
4.3
14.2
70
294
N06CA01
ATC
amitriptyline and psycholeptics; systemic
5.4
14.1
34
82
G04BD
ATC
Drugs for urinary frequency and incontinence
157.0
13.8
14
*
N31.1
ICD-10 Finland
Reflex neuropathic bladder, not elsewhere classified
45.6
13.5
16
*
N30.9
ICD-10 Finland
Cystitis, unspecified
5.4
11.9
27
61
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
5.7
11.8
25
53
KCV02
NOMESCO Finland
Cystoscopic balloon distension of bladder
+∞
11.6
11
*
L04AA01
ATC
[U] ciclosporin
28.3
11.5
15
6
7321
FHL
TU biopsy, coagulation or laser
+∞
10.6
10
*
J01MA02
ATC
ciprofloxacin; systemic
3.6
10.5
74
373
N02AX02
ATC
tramadol; systemic, rectal
3.5
10.4
75
384
UJF32
NOMESCO Finland
Coloscopy
3.5
10.3
53
219
TKC20
NOMESCO Finland
Catheterisation of bladder
5.5
10.2
22
47
P01BA02
ATC
hydroxychloroquine; oral
4.5
9.7
27
72
G04AC01, ,
ATC
9.0
9.6
20
26
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.2
9.2
59
276
G04BD01
ATC
emepronium; systemic
20.6
9.2
13
7
N32.82
ICD-10 Finland
Instability of the detrusor vesicae muscle
26.4
9.1
12
5
A03FA02
ATC
cisapride; oral, rectal
4.7
8.8
23
58
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
3.1
8.8
65
328
J01MA01
ATC
ofloxacin; systemic
4.5
8.7
24
63
R30.0
ICD-10 Finland
Dysuria
8.1
8.7
19
27
N06AA09
ATC
amitriptyline; systemic
4.0
8.2
27
81
R01AD12
ATC
fluticasone furoate; nasal
3.1
8.0
50
226
XKD06
NOMESCO Finland
Physiologic investigation of micturition
9.9
7.8
15
17
R30.1
ICD-10 Finland
Vesical tenesmus
13.1
7.8
13
11
G04BD12
ATC
mirabegron; oral
3.7
7.7
29
96
G44.2
ICD-10 Finland
Tension-type headache
3.6
7.2
28
94
A03CA02
ATC
clidinium and psycholeptics; oral
4.6
7.1
18
44
R10.3
ICD-10 Finland
Pain localized to other parts of lower abdomen
2.9
6.8
42
187
ZXD10
NOMESCO Finland
Scheduled procedure
2.7
6.8
64
355
J01CA08
ATC
pivmecillinam; oral
2.9
6.5
85
550
G03CA04
ATC
estriol; systemic, vaginal
3.5
6.5
25
83
90621, ,
NOMESCO Finland
73.6
6.5
7
*
D13.1
ICD-10 Finland
Benign neoplasm: Stomach
12.0
6.4
11
10
G04BD11
ATC
fesoterodine; oral
7.8
6.4
14
20
J01EE02
ATC
sulfadiazine and trimethoprim; systemic
2.7
6.4
52
266
7362
FHL
Urethral dilatation in anesthesia or operating room
+∞
6.3
6
*
KCC00
NOMESCO Finland
Cystectomy
+∞
6.3
6
*
U07
ICPC
Urine symptom/complaint other
3.6
6.3
23
74
A02BA02
ATC
ranitidine; systemic
2.8
6.2
39
174

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Pharmacy visit
OMOP4822462 [581458]
1.3e+00
2.0e+00
8.1e-01
2.2e+00
1.2e+00
1.7e+00
1.0e+50
cases:97.48%
controls:91.49%
cases:95.80%
controls:74.89%
cases:49.58%
controls:30.33%
cases:12.61%
controls:1.60%
cases:57.98%
controls:30.33%
cases:94.96%
controls:76.60%
cases:100.00%
controls:93.26%
116
1086
3
101
114
889
5
298
59
360
60
827
15
19
104
1168
69
360
50
827
113
907
6
277
119
1080
0
78
General Surgery
2 [38004447]
1.4e+00
2.2e+00
2.5e+00
—
3.2e+00
2.9e+00
1.5e+00
cases:50.42%
controls:19.97%
cases:48.74%
controls:9.44%
cases:15.13%
controls:1.43%
—
—
cases:33.61%
controls:2.11%
cases:71.43%
controls:12.16%
cases:63.03%
controls:27.12%
60
237
59
950
58
112
61
1075
18
17
101
1170
—
40
25
79
1162
85
144
34
1040
75
314
44
844
Outpatient Visit
OP [9202]
1.1e+00
1.4e+00
1.5e+00
—
2.4e+00
2.3e+00
1.9e+00
cases:42.02%
controls:19.38%
cases:54.62%
controls:23.17%
cases:21.85%
controls:5.73%
—
—
cases:41.18%
controls:5.73%
cases:80.67%
controls:30.32%
cases:90.76%
controls:60.54%
50
230
69
957
65
275
54
912
26
68
93
1119
—
49
68
70
1119
96
359
23
825
108
701
11
457
oxybutynin; oral, transdermal
G04BD04 [21602637]
3.4e+00
2.9e+00
—
—
1.0e+50
—
3.0e+00
cases:29.41%
controls:1.35%
cases:12.61%
controls:0.76%
—
—
—
—
cases:4.20%
controls:0.00%
—
—
cases:13.45%
controls:0.78%
35
16
84
1171
15
9
104
1178
—
—
5
0
114
1187
—
16
9
103
1149
norfloxacin; oral
J01MA06 [21603013]
1.9e+00
2.2e+00
—
—
—
2.9e+00
1.9e+00
cases:15.13%
controls:2.70%
cases:7.56%
controls:0.93%
—
—
—
—
—
—
cases:8.40%
controls:0.51%
cases:21.01%
controls:3.71%
18
32
101
1155
9
11
110
1176
—
—
—
10
6
109
1178
25
43
94
1115
Outpatient Hospital
22 [8756]
1.4e+00
2.0e+00
2.2e+00
—
2.3e+00
1.9e+00
1.1e+00
cases:55.46%
controls:22.91%
cases:37.82%
controls:7.50%
cases:4.20%
controls:0.51%
—
—
cases:10.92%
controls:1.18%
cases:34.45%
controls:7.43%
cases:51.26%
controls:26.17%
66
272
53
915
45
89
74
1098
5
6
114
1181
—
13
14
106
1173
41
88
78
1096
61
303
58
855
Obstetrics / Gynecology
16 [38004461]
9.0e-01
1.6e+00
2.5e+00
1.0e+50
2.2e+00
1.2e+00
7.0e-01
cases:26.89%
controls:12.97%
cases:21.01%
controls:4.89%
cases:5.04%
controls:0.42%
cases:9.24%
controls:0.00%
cases:5.88%
controls:0.67%
cases:19.33%
controls:6.84%
cases:32.77%
controls:19.52%
32
154
87
1033
25
58
94
1129
6
5
113
1182
11
0
108
1187
7
8
112
1179
23
81
96
1103
39
226
80
932
nitrofurantoin; oral
J01XE01 [21603058]
1.6e+00
2.1e+00
—
—
—
2.7e+00
1.9e+00
cases:8.40%
controls:1.85%
cases:5.04%
controls:0.67%
—
—
—
—
—
—
cases:9.24%
controls:0.68%
cases:8.40%
controls:1.38%
10
22
109
1165
6
8
113
1179
—
—
—
11
8
108
1176
10
16
109
1142
Inpatient Hospital
21 [8717]
1.2e+00
1.6e+00
1.6e+00
1.0e+50
2.1e+00
1.4e+00
1.0e+00
cases:63.03%
controls:34.29%
cases:40.34%
controls:11.54%
cases:5.04%
controls:1.10%
cases:5.04%
controls:0.00%
cases:12.61%
controls:1.68%
cases:36.13%
controls:12.16%
cases:61.34%
controls:36.44%
75
407
44
780
48
137
71
1050
6
13
113
1174
6
0
113
1187
15
20
104
1167
43
144
76
1040
73
422
46
736
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
1.5e+00
2.0e+00
—
—
—
2.0e+00
1.5e+00
cases:14.29%
controls:3.45%
cases:8.40%
controls:1.18%
—
—
—
—
—
—
cases:8.40%
controls:1.27%
cases:19.33%
controls:5.18%
17
41
102
1146
10
14
109
1173
—
—
—
10
15
109
1169
23
60
96
1098
trimethoprim; oral, parenteral
J01EA01 [21602931]
1.4e+00
1.7e+00
—
—
—
1.7e+00
1.5e+00
cases:19.33%
controls:5.48%
cases:6.72%
controls:1.35%
—
—
—
—
—
—
cases:10.92%
controls:2.20%
cases:15.13%
controls:3.80%
23
65
96
1122
8
16
111
1171
—
—
—
13
26
106
1158
18
44
101
1114
ketoprofen; ointment
M02AA10 [21604046]
1.4e+00
2.2e+00
—
—
—
2.2e+00
—
cases:9.24%
controls:2.44%
cases:6.72%
controls:0.76%
—
—
—
—
—
—
cases:5.04%
controls:0.59%
—
—
11
29
108
1158
8
9
111
1178
—
—
—
6
7
113
1177
—
One hour or less
ZXE00 [2001311394]
—
1.9e+00
—
—
—
2.5e+00
1.2e+00
—
—
cases:5.88%
controls:0.93%
—
—
—
—
—
—
cases:11.76%
controls:1.10%
cases:17.65%
controls:5.96%
—
7
11
112
1176
—
—
—
14
13
105
1171
21
69
98
1089
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
8.0e-01
2.0e+00
—
—
—
2.1e+00
1.4e+00
cases:7.56%
controls:3.54%
cases:13.45%
controls:2.11%
—
—
—
—
—
—
cases:14.29%
controls:2.03%
cases:22.69%
controls:6.74%
9
42
110
1145
16
25
103
1162
—
—
—
17
24
102
1160
27
78
92
1080
Scheduled procedure
ZXD10 [2001311387]
—
1.9e+00
—
—
—
2.1e+00
1.3e+00
—
—
cases:7.56%
controls:1.26%
—
—
—
—
—
—
cases:13.45%
controls:1.86%
cases:23.53%
controls:7.94%
—
9
15
110
1172
—
—
—
16
22
103
1162
28
92
91
1066
fluconazole; oral, parenteral
J02AC01 [21603080]
1.2e+00
2.0e+00
-1.0e+50
—
-1.0e+50
1.1e+00
1.1e+00
cases:21.01%
controls:7.41%
cases:13.45%
controls:2.11%
cases:0.00%
controls:0.42%
—
—
cases:0.00%
controls:0.76%
cases:10.92%
controls:3.97%
cases:23.53%
controls:9.67%
25
88
94
1099
16
25
103
1162
0
5
119
1182
—
0
9
119
1178
13
47
106
1137
28
112
91
1046
miconazole; vaginal
G01AF04 [21602394]
1.7e+00
—
—
—
—
—
2.3e+00
cases:6.72%
controls:1.35%
—
—
—
—
—
—
—
—
—
—
cases:5.04%
controls:0.52%
8
16
111
1171
—
—
—
—
—
6
6
113
1152
Other and unspecified abdominal pain
R10.4 [45568113]
—
2.2e+00
—
—
—
—
1.6e+00
—
—
cases:5.88%
controls:0.67%
—
—
—
—
—
—
—
—
cases:18.49%
controls:4.23%
—
7
8
112
1179
—
—
—
—
22
49
97
1109
hydroxychloroquine; oral
P01BA02 [21604889]
1.9e+00
2.2e+00
—
—
—
—
1.8e+00
cases:5.88%
controls:0.93%
cases:4.20%
controls:0.51%
—
—
—
—
—
—
—
—
cases:7.56%
controls:1.38%
7
11
112
1176
5
6
114
1181
—
—
—
—
9
16
110
1142
sulfadiazine and trimethoprim
J01EE02 [21602962]
1.6e+00
2.0e+00
—
—
—
1.3e+00
1.1e+00
cases:28.57%
controls:7.41%
cases:10.92%
controls:1.68%
—
—
—
—
—
—
cases:5.88%
controls:1.69%
cases:10.08%
controls:3.54%
34
88
85
1099
13
20
106
1167
—
—
—
7
20
112
1164
12
41
107
1117
cisapride; oral, rectal
A03FA02 [21600485]
1.7e+00
1.9e+00
—
—
—
—
—
cases:13.45%
controls:2.78%
cases:6.72%
controls:1.10%
—
—
—
—
—
—
—
—
—
—
16
33
103
1154
8
13
111
1174
—
—
—
—
—
Urology
34 [38004474]
—
—
—
1.0e+50
—
—
3.5e+00
—
—
—
—
—
—
cases:8.40%
controls:0.00%
—
—
—
—
cases:31.93%
controls:1.38%
—
—
—
10
0
109
1187
—
—
38
16
81
1142
Cystoscopy
UKC02 [2001306005]
—
—
—
1.0e+50
1.0e+50
—
3.0e+00
—
—
—
—
—
—
cases:10.92%
controls:0.00%
cases:7.56%
controls:0.00%
—
—
cases:15.13%
controls:0.86%
—
—
—
13
0
106
1187
9
0
110
1187
—
18
10
101
1148
lansoprazole; oral
A02BC03 [21600098]
1.4e+00
1.1e+00
—
—
—
1.4e+00
1.4e+00
cases:9.24%
controls:2.44%
cases:4.20%
controls:1.43%
—
—
—
—
—
—
cases:5.04%
controls:1.35%
cases:22.69%
controls:6.65%
11
29
108
1158
5
17
114
1170
—
—
—
6
16
113
1168
27
77
92
1081
pivmecillinam; oral
J01CA08 [21602827]
1.3e+00
1.1e+00
—
—
—
1.4e+00
7.6e-01
cases:17.65%
controls:5.73%
cases:7.56%
controls:2.70%
—
—
—
—
—
—
cases:10.92%
controls:2.87%
cases:20.17%
controls:10.54%
21
68
98
1119
9
32
110
1155
—
—
—
13
34
106
1150
24
122
95
1036
tolterodine; oral
G04BD07 [21602640]
—
—
—
—
—
—
2.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:18.49%
controls:1.73%
—
—
—
—
—
—
22
20
97
1138
zopiclone; oral
N05CF01 [21604654]
8.2e-01
3.7e-01
2.5e+00
—
—
7.3e-01
8.6e-01
cases:10.92%
controls:5.14%
cases:5.04%
controls:3.54%
cases:5.04%
controls:0.42%
—
—
—
—
cases:7.56%
controls:3.80%
cases:14.29%
controls:6.56%
13
61
106
1126
6
42
113
1145
6
5
113
1182
—
—
9
45
110
1139
17
76
102
1082
Office Visit
OMOP4822458 [581477]
—
7.5e-01
—
—
—
1.5e+00
9.8e-01
—
—
cases:4.20%
controls:2.02%
—
—
—
—
—
—
cases:9.24%
controls:2.28%
cases:20.17%
controls:8.64%
—
5
24
114
1163
—
—
—
11
27
108
1157
24
100
95
1058
loratadine; oral
R06AX13 [21603514]
1.1e+00
—
—
—
—
2.3e+00
1.3e+00
cases:6.72%
controls:2.44%
—
—
—
—
—
—
—
—
cases:5.88%
controls:0.59%
cases:7.56%
controls:2.25%
8
29
111
1158
—
—
—
—
7
7
112
1177
9
26
110
1132
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.88%
controls:0.60%
—
—
—
—
—
—
7
7
112
1151
Otolaryngology
4 [38004449]
3.5e-01
9.1e-01
—
—
—
1.4e+00
8.5e-01
cases:5.04%
controls:3.62%
cases:5.88%
controls:2.44%
—
—
—
—
—
—
cases:9.24%
controls:2.36%
cases:20.17%
controls:9.76%
6
43
113
1144
7
29
112
1158
—
—
—
11
28
108
1156
24
113
95
1045
ketoprofen; oral, parenteral, rectal
M01AE03 [21603969]
9.4e-01
1.0e+00
—
—
—
1.2e+00
8.5e-01
cases:31.93%
controls:15.50%
cases:10.08%
controls:3.88%
—
—
—
—
—
—
cases:11.76%
controls:3.80%
cases:14.29%
controls:6.65%
38
184
81
1003
12
46
107
1141
—
—
—
14
45
105
1139
17
77
102
1081
methenamine; oral
J01XX05 [21603065]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.88%
controls:0.78%
—
—
—
—
—
—
7
9
112
1149
pseudoephedrine, combinations; oral
R01BA52 [21603213]
8.7e-01
1.2e+00
—
—
-1.0e+50
3.5e-01
4.5e-01
cases:32.77%
controls:16.93%
cases:11.76%
controls:3.88%
—
—
—
—
cases:0.00%
controls:0.51%
cases:5.88%
controls:4.22%
cases:15.97%
controls:10.79%
39
201
80
986
14
46
105
1141
—
—
0
6
119
1181
7
50
112
1134
19
125
100
1033
Other primary gonarthrosis
M17.1 [45596493]
2.1e+00
—
—
—
—
—
1.1e+00
cases:5.04%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
cases:5.04%
controls:1.73%
6
8
113
1179
—
—
—
—
—
6
20
113
1138
Internal Medicine
11 [38004456]
5.6e-01
7.4e-01
1.2e+00
1.0e+50
1.4e+00
1.1e+00
8.4e-01
cases:17.65%
controls:10.95%
cases:15.13%
controls:7.83%
cases:5.88%
controls:1.94%
cases:5.04%
controls:0.00%
cases:7.56%
controls:1.94%
cases:24.37%
controls:9.54%
cases:42.86%
controls:24.53%
21
130
98
1057
18
93
101
1094
7
23
112
1164
6
0
113
1187
9
23
110
1164
29
113
90
1071
51
284
68
874
ofloxacin; oral, parenteral
J01MA01 [21603008]
1.6e+00
—
—
—
—
—
1.9e+00
cases:5.88%
controls:1.26%
—
—
—
—
—
—
—
—
—
—
cases:8.40%
controls:1.38%
7
15
112
1172
—
—
—
—
—
10
16
109
1142
clidinium and psycholeptics
A03CA02 [21600204]
1.9e+00
—
—
—
—
—
1.3e+00
cases:7.56%
controls:1.26%
—
—
—
—
—
—
—
—
—
—
cases:7.56%
controls:2.25%
9
15
110
1172
—
—
—
—
—
9
26
110
1132
ispaghula (psylla seeds); oral
A06AC01 [21600555]
—
—
—
—
—
2.1e+00
1.8e+00
—
—
—
—
—
—
—
—
—
—
cases:4.20%
controls:0.51%
cases:10.08%
controls:1.81%
—
—
—
—
—
5
6
114
1178
12
21
107
1137
dextropropoxyphene; oral
N02AC04 [21604278]
1.8e+00
—
—
—
—
-1.0e+50
—
cases:6.72%
controls:1.18%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
8
14
111
1173
—
—
—
—
0
6
119
1178
—
Pain localized to other parts of lower abdomen
R10.3 [45534426]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.56%
controls:1.38%
—
—
—
—
—
—
9
16
110
1142
triamcinolone; nasal
R01AD11 [21605052]
—
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.40%
controls:1.64%
—
—
—
—
—
—
10
19
109
1139
indometacin; oral, parenteral, rectal
M01AB01 [21603941]
1.7e+00
—
—
—
—
—
—
cases:6.72%
controls:1.35%
—
—
—
—
—
—
—
—
—
—
—
—
8
16
111
1171
—
—
—
—
—
—
indometacin
C01EB03 [21600365]
1.7e+00
—
—
—
—
—
—
cases:6.72%
controls:1.35%
—
—
—
—
—
—
—
—
—
—
—
—
8
16
111
1171
—
—
—
—
—
—
Orthopedic Surgery
20 [38004465]
1.7e+00
—
—
—
—
—
6.4e-01
cases:10.92%
controls:2.27%
—
—
—
—
—
—
—
—
—
—
cases:15.97%
controls:9.07%
13
27
106
1160
—
—
—
—
—
19
105
100
1053
amitriptyline; oral, parenteral
N06AA09 [21604696]
—
1.5e+00
—
—
—
1.7e+00
1.6e+00
—
—
cases:4.20%
controls:0.93%
—
—
—
—
—
—
cases:5.04%
controls:0.93%
cases:10.08%
controls:2.16%
—
5
11
114
1176
—
—
—
6
11
113
1173
12
25
107
1133
misoprostol; oral, vaginal
G02AD06 [21602443]
1.6e+00
—
—
—
—
—
—
cases:9.24%
controls:2.02%
—
—
—
—
—
—
—
—
—
—
—
—
11
24
108
1163
—
—
—
—
—
—
misoprostol; oral
A02BB01 [21600093]
1.6e+00
—
—
—
—
—
—
cases:9.24%
controls:2.02%
—
—
—
—
—
—
—
—
—
—
—
—
11
24
108
1163
—
—
—
—
—
—
Rheumatology
66 [38004491]
1.9e+00
—
—
—
—
—
1.6e+00
cases:4.20%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
cases:9.24%
controls:2.07%
5
8
114
1179
—
—
—
—
—
11
24
108
1134
estradiol; nasal, oral, parenteral, rectal, transdermal, vaginal
G03CA03 [21602517]
5.9e-01
8.2e-01
1.1e+00
—
7.5e-01
6.7e-01
7.2e-01
cases:24.37%
controls:15.16%
cases:25.21%
controls:12.89%
cases:9.24%
controls:3.20%
—
—
cases:6.72%
controls:3.29%
cases:24.37%
controls:14.19%
cases:40.34%
controls:24.70%
29
180
90
1007
30
153
89
1034
11
38
108
1149
—
8
39
111
1148
29
168
90
1016
48
286
71
872
ranitidine bismuth citrate; oral
A02BA07 [21600088]
1.5e+00
1.0e+00
—
—
-1.0e+50
1.0e+00
7.5e-01
cases:19.33%
controls:4.89%
cases:5.04%
controls:1.85%
—
—
—
—
cases:0.00%
controls:0.42%
cases:5.88%
controls:2.20%
cases:9.24%
controls:4.58%
23
58
96
1129
6
22
113
1165
—
—
0
5
119
1182
7
26
112
1158
11
53
108
1105
ranitidine; oral, parenteral
A02BA02 [21600083]
1.5e+00
1.0e+00
—
—
-1.0e+50
1.0e+00
7.5e-01
cases:19.33%
controls:4.89%
cases:5.04%
controls:1.85%
—
—
—
—
cases:0.00%
controls:0.42%
cases:5.88%
controls:2.20%
cases:9.24%
controls:4.58%
23
58
96
1129
6
22
113
1165
—
—
0
5
119
1182
7
26
112
1158
11
53
108
1105
diclofenac, combinations; oral
M01AB55 [21603959]
1.5e+00
—
—
—
—
—
—
cases:7.56%
controls:1.77%
—
—
—
—
—
—
—
—
—
—
—
—
9
21
110
1166
—
—
—
—
—
—
prednisone; oral
H02AB07 [21602735]
1.5e+00
—
—
—
—
—
—
cases:7.56%
controls:1.77%
—
—
—
—
—
—
—
—
—
—
—
—
9
21
110
1166
—
—
—
—
—
—
prednisone
A07EA03 [21600655]
1.5e+00
—
—
—
—
—
—
cases:7.56%
controls:1.77%
—
—
—
—
—
—
—
—
—
—
—
—
9
21
110
1166
—
—
—
—
—
—
amitriptyline and psycholeptics
N06CA01 [21604789]
1.4e+00
—
—
—
—
—
1.5e+00
cases:8.40%
controls:2.27%
—
—
—
—
—
—
—
—
—
—
cases:8.40%
controls:2.07%
10
27
109
1160
—
—
—
—
—
10
24
109
1134
propranolol; oral, parenteral
C07AA05 [21601670]
1.4e+00
—
—
—
—
—
1.1e+00
cases:10.08%
controls:2.70%
—
—
—
—
—
—
—
—
—
—
cases:5.04%
controls:1.81%
12
32
107
1155
—
—
—
—
—
6
21
113
1137
tizanidine; oral
M03BX02 [21604116]
3.6e-01
6.2e-01
—
—
—
1.3e+00
5.7e-01
cases:14.29%
controls:10.45%
cases:5.04%
controls:2.78%
—
—
—
—
—
—
cases:10.08%
controls:2.96%
cases:18.49%
controls:11.40%
17
124
102
1063
6
33
113
1154
—
—
—
12
35
107
1149
22
132
97
1026
More than one and less than three hours
ZXE10 [2001311401]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:12.61%
controls:3.97%
—
—
—
—
—
—
15
46
104
1112
cetirizine; oral
R06AE07 [21603497]
1.1e+00
8.9e-01
—
—
-1.0e+50
5.8e-01
6.0e-01
cases:23.53%
controls:8.93%
cases:8.40%
controls:3.62%
—
—
—
—
cases:0.00%
controls:0.42%
cases:6.72%
controls:3.89%
cases:15.97%
controls:9.41%
28
106
91
1081
10
43
109
1144
—
—
0
5
119
1182
8
46
111
1138
19
109
100
1049
rofecoxib; oral
M01AH02 [21603993]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:16.81%
controls:6.48%
—
—
—
—
—
—
20
75
99
1083
paracetamol, combinations excl. psycholeptics
N02BE51 [21604348]
1.1e+00
1.6e+00
—
—
—
—
—
cases:12.61%
controls:4.80%
cases:5.88%
controls:1.26%
—
—
—
—
—
—
—
—
—
—
15
57
104
1130
7
15
112
1172
—
—
—
—
—
acrivastine; oral
R06AX18 [21603518]
1.0e+00
1.1e+00
—
—
-1.0e+50
5.8e-01
7.3e-01
cases:24.37%
controls:10.28%
cases:10.08%
controls:3.45%
—
—
—
—
cases:0.00%
controls:0.42%
cases:5.04%
controls:2.87%
cases:8.40%
controls:4.23%
29
122
90
1065
12
41
107
1146
—
—
0
5
119
1182
6
34
113
1150
10
49
109
1109
metronidazole; oral, rectal
P01AB01 [21604857]
1.0e+00
1.4e+00
—
—
—
1.7e+00
1.0e+00
cases:21.85%
controls:9.10%
cases:7.56%
controls:2.02%
—
—
—
—
—
—
cases:5.04%
controls:0.93%
cases:7.56%
controls:2.85%
26
108
93
1079
9
24
110
1163
—
—
—
6
11
113
1173
9
33
110
1125
cefalexin; oral
J01DB01 [21602870]
1.0e+00
7.8e-01
—
—
—
7.7e-01
4.5e-01
cases:42.86%
controls:21.23%
cases:14.29%
controls:7.08%
—
—
—
—
—
—
cases:15.97%
controls:8.11%
cases:36.97%
controls:27.29%
51
252
68
935
17
84
102
1103
—
—
—
19
96
100
1088
44
316
75
842
azithromycin; oral, parenteral
J01FA10 [21602978]
6.6e-01
1.0e+00
—
—
—
3.9e-01
8.3e-01
cases:21.01%
controls:12.05%
cases:12.61%
controls:4.89%
—
—
—
—
—
—
cases:5.88%
controls:4.05%
cases:25.21%
controls:12.78%
25
143
94
1044
15
58
104
1129
—
—
—
7
48
112
1136
30
148
89
1010
naproxen; oral, rectal
M01AE02 [21603968]
7.4e-01
3.8e-01
—
—
—
7.5e-01
6.2e-01
cases:30.25%
controls:17.10%
cases:7.56%
controls:5.31%
—
—
—
—
—
—
cases:8.40%
controls:4.14%
cases:12.61%
controls:7.17%
36
203
83
984
9
63
110
1124
—
—
—
10
49
109
1135
15
83
104
1075
naproxcinod
M01AE18 [40254094]
7.4e-01
3.8e-01
—
—
—
7.5e-01
6.2e-01
cases:30.25%
controls:17.10%
cases:7.56%
controls:5.31%
—
—
—
—
—
—
cases:8.40%
controls:4.14%
cases:12.61%
controls:7.17%
36
203
83
984
9
63
110
1124
—
—
—
10
49
109
1135
15
83
104
1075
Emergency Room Visit
ER [9203]
5.5e-01
6.8e-01
1.9e+00
1.0e+50
—
8.1e-01
7.4e-01
cases:9.24%
controls:5.56%
cases:10.08%
controls:5.39%
cases:4.20%
controls:0.67%
cases:8.40%
controls:0.00%
—
—
cases:18.49%
controls:9.21%
cases:48.74%
controls:31.26%
11
66
108
1121
12
64
107
1123
5
8
114
1179
10
0
109
1187
—
22
109
97
1075
58
362
61
796
amoxicillin; oral, parenteral
J01CA04 [21602823]
7.3e-01
6.5e-01
—
—
—
7.5e-01
3.0e-01
cases:30.25%
controls:17.35%
cases:8.40%
controls:4.55%
—
—
—
—
—
—
cases:10.92%
controls:5.49%
cases:25.21%
controls:20.03%
36
206
83
981
10
54
109
1133
—
—
—
13
65
106
1119
30
232
89
926
Ophthalmology
18 [38004463]
8.4e-02
1.3e-01
-1.0e+50
—
-1.0e+50
—
6.2e-02
cases:4.20%
controls:3.88%
cases:4.20%
controls:3.71%
cases:0.00%
controls:0.67%
—
—
cases:0.00%
controls:0.42%
—
—
cases:11.76%
controls:11.14%
5
46
114
1141
5
44
114
1143
0
8
119
1179
—
0
5
119
1182
—
14
129
105
1029
Other primary coxarthrosis
M16.1 [45591741]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
0
5
119
1182
—
—
—
—
0
5
119
1153
prednisolone; oral, parenteral
H02AB06 [21602734]
1.5e-01
1.3e+00
—
—
—
—
5.4e-02
cases:4.20%
controls:3.62%
cases:5.04%
controls:1.43%
—
—
—
—
—
—
—
—
cases:6.72%
controls:6.39%
5
43
114
1144
6
17
113
1170
—
—
—
—
8
74
111
1084
lisinopril and diuretics
C09BA03 [21601805]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.59%
cases:0.00%
controls:0.76%
—
—
—
—
—
—
cases:0.00%
controls:0.68%
cases:0.00%
controls:1.12%
0
7
119
1180
0
9
119
1178
—
—
—
0
8
119
1176
0
13
119
1145
hydrocortisone butyrate
D07AB02 [21602106]
6.5e-01
—
—
—
—
—
-2.9e-02
cases:13.45%
controls:7.50%
—
—
—
—
—
—
—
—
—
—
cases:6.72%
controls:6.91%
16
89
103
1098
—
—
—
—
—
8
80
111
1078
Polyp of cervix uteri
N84.1 [45567867]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
0
5
119
1153
doxycycline; oral, parenteral
J01AA02 [21602800]
5.0e-01
5.5e-01
—
—
—
-5.6e-03
4.3e-01
cases:41.18%
controls:29.74%
cases:11.76%
controls:7.16%
—
—
—
—
—
—
cases:9.24%
controls:9.29%
cases:24.37%
controls:17.36%
49
353
70
834
14
85
105
1102
—
—
—
11
110
108
1074
29
201
90
957
prednisolone
A07EA01 [21600653]
1.5e-01
1.5e+00
—
—
—
—
5.4e-02
cases:4.20%
controls:3.62%
cases:5.88%
controls:1.43%
—
—
—
—
—
—
—
—
cases:6.72%
controls:6.39%
5
43
114
1144
7
17
112
1170
—
—
—
—
8
74
111
1084
pantoprazole; oral, parenteral
A02BC02 [21600097]
—
—
—
—
—
—
6.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.08%
controls:5.53%
—
—
—
—
—
—
12
64
107
1094
cinchocaine
C05AD04 [21601621]
2.2e+00
—
—
—
—
—
—
cases:4.20%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
—
5
6
114
1181
—
—
—
—
—
—
celecoxib
L01XX33 [21603805]
—
—
—
—
—
—
8.2e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:12.61%
controls:5.96%
—
—
—
—
—
—
15
69
104
1089
antibiotics in combination with other drugs
S01AA20 [21603571]
2.5e-01
—
—
—
—
—
7.0e-01
cases:5.88%
controls:4.63%
—
—
—
—
—
—
—
—
—
—
cases:6.72%
controls:3.45%
7
55
112
1132
—
—
—
—
—
8
40
111
1118
Lumbar and other intervertebral disc disorders with radiculopathy
M51.1 [45562747]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
119
1180
—
—
—
—
—
—
fluorometholone
S01BA07 [21603624]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
0
6
119
1181
—
—
—
—
—
0
5
119
1153
diphenhydramine, combinations
R06AA52 [21603454]
4.5e-01
—
—
—
—
—
7.1e-02
cases:11.76%
controls:7.83%
—
—
—
—
—
—
—
—
—
—
cases:7.56%
controls:7.08%
14
93
105
1094
—
—
—
—
—
9
82
110
1076
Gastroscopy
UJD02 [2001304787]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
119
1179
—
—
—
—
—
—
Spontaneous vertex delivery
O80.0 [45577661]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
cases:0.00%
controls:0.76%
cases:0.00%
controls:2.42%
—
0
8
119
1179
—
—
—
0
9
119
1175
0
28
119
1130
policresulen; vaginal
G01AX03 [21602413]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
119
1182
—
—
—
—
—
—
Other hypothyroidism
E03 [45581337]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
0
7
119
1151
chlorhexidine
D09AA12 [21602275]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
0
7
119
1180
—
—
—
0
9
119
1175
—
Irregular menstruation, unspecified
N92.6 [45539075]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
0
7
119
1151
Adhesive capsulitis of shoulder
M75.0 [45533931]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
6
119
1152
Fractional scraping
8113 [2000101291]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
119
1177
—
—
—
—
—
—
General Practice
1 [38004446]
3.9e-01
—
—
—
—
1.3e+00
-5.3e-01
cases:5.88%
controls:4.04%
—
—
—
—
—
—
—
—
cases:5.88%
controls:1.69%
cases:4.20%
controls:6.91%
7
48
112
1139
—
—
—
—
7
20
112
1164
5
80
114
1078
Essential (primary) hypertension
I10 [45591453]
1.2e+00
—
—
—
—
—
-7.7e-02
cases:5.04%
controls:1.60%
—
—
—
—
—
—
—
—
—
—
cases:7.56%
controls:8.12%
6
19
113
1168
—
—
—
—
—
9
94
110
1064
lercanidipine; oral
C08CA13 [21601759]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
0
14
119
1144
hydrocortisone
D07AA02 [21602102]
6.5e-01
—
—
—
—
—
-2.9e-02
cases:13.45%
controls:7.50%
—
—
—
—
—
—
—
—
—
—
cases:6.72%
controls:6.91%
16
89
103
1098
—
—
—
—
—
8
80
111
1078
Intravesicalis
ZX136 [2001311504]
—
—
—
—
—
1.0e+50
1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:4.20%
controls:0.00%
cases:4.20%
controls:0.00%
—
—
—
—
—
5
0
114
1184
5
0
114
1158
long-acting sulfonamides - combinations
J01ED20 [21602959]
4.5e-01
—
—
—
—
—
7.1e-02
cases:11.76%
controls:7.83%
—
—
—
—
—
—
—
—
—
—
cases:7.56%
controls:7.08%
14
93
105
1094
—
—
—
—
—
9
82
110
1076
insulin aspart; parenteral
A10AD05 [21600733]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.25%
—
—
—
—
—
—
0
26
119
1132
Photography of fundus of eye
XCK10 [2001301381]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.95%
—
—
—
—
—
—
0
11
119
1147
Intramural leiomyoma of uterus
D25.1 [45547585]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
119
1180
—
—
—
—
—
—
combinations of corticosteroids
D07XB30 [21602188]
5.5e-01
—
—
—
-1.0e+50
—
2.5e-01
cases:14.29%
controls:8.76%
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
cases:11.76%
controls:9.41%
17
104
102
1083
—
—
—
0
5
119
1182
—
14
109
105
1049
potassium chloride; oral
A12BA01 [21600877]
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
cases:0.00%
controls:1.18%
—
—
—
—
—
—
0
5
119
1182
0
14
119
1170
—
fluticasone furoate
R03BA09 [45893496]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.56%
controls:2.50%
—
—
—
—
—
—
9
29
110
1129
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
—
9.4e-01
—
—
—
1.4e+00
8.4e-01
—
—
cases:4.20%
controls:1.68%
—
—
—
—
—
—
cases:6.72%
controls:1.77%
cases:10.92%
controls:5.01%
—
5
20
114
1167
—
—
—
8
21
111
1163
13
58
106
1100
Dyspnoea
R06.0 [45558449]
-1.0e+50
—
—
—
—
—
1.3e+00
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
cases:5.04%
controls:1.47%
0
5
119
1182
—
—
—
—
—
6
17
113
1141
betamethasone
S02BA07 [21605169]
1.3e-01
—
—
—
—
—
—
cases:4.20%
controls:3.71%
—
—
—
—
—
—
—
—
—
—
—
—
5
44
114
1143
—
—
—
—
—
—
hydrocortisone
A07EA02 [21600654]
6.1e-01
—
—
—
—
—
-5.6e-02
cases:13.45%
controls:7.75%
—
—
—
—
—
—
—
—
—
—
cases:6.72%
controls:7.08%
16
92
103
1095
—
—
—
—
—
8
82
111
1076
Contusion of knee
S80.0 [45569633]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
0
5
119
1153
Laparoscopic sterilisation by constriction of Fallopian tubes
LGA21 [2001306793]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.69%
0
10
119
1177
—
—
—
—
—
0
8
119
1150
Anastomosis to coronary artery from internal mammary artery, one distal anastamosis
FNA01 [2001303015]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
0
5
119
1153
amides - combinations
N01BB20 [21604239]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.69%
—
—
—
—
—
—
0
8
119
1150
triamcinolone and antiseptics
D07BB03 [21602150]
9.9e-01
—
—
—
—
-1.0e+50
—
cases:5.04%
controls:1.94%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.10%
—
—
6
23
113
1164
—
—
—
—
0
13
119
1171
—
Psychiatry
26 [38004469]
—
—
—
—
1.9e+00
—
1.0e+00
—
—
—
—
—
—
—
—
cases:4.20%
controls:0.67%
—
—
cases:10.08%
controls:3.80%
—
—
—
—
5
8
114
1179
—
12
44
107
1114
Bladder stretching
7325 [2000101179]
1.0e+50
—
—
—
—
—
—
cases:15.13%
controls:0.00%
—
—
—
—
—
—
—
—
—
—
—
—
18
0
101
1187
—
—
—
—
—
—
econazole
D01AC03 [21601922]
1.4e+00
—
—
—
—
—
1.3e+00
cases:5.04%
controls:1.35%
—
—
—
—
—
—
—
—
—
—
cases:4.20%
controls:1.12%
6
16
113
1171
—
—
—
—
—
5
13
114
1145
Chronic coronary artery disease and dyslipidaemia associated with chronic coronary artery disease
206 [2001600204]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
0
5
119
1179
—
phenylpropanolamine, combinations; oral
R01BA51 [21603212]
4.4e-01
—
—
—
—
—
3.2e-02
cases:12.61%
controls:8.51%
—
—
—
—
—
—
—
—
—
—
cases:7.56%
controls:7.34%
15
101
104
1086
—
—
—
—
—
9
85
110
1073
Uroflowmetry
44856007 [4261340]
—
1.0e+50
—
—
—
—
—
—
—
cases:5.88%
controls:0.00%
—
—
—
—
—
—
—
—
—
—
—
7
0
112
1187
—
—
—
—
—
Type 1 diabetes mellitus, With ophthalmic complications
E10.3 [45552380]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
0
7
119
1151
metronidazole and furazolidone
P01AB51 [45893518]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
0
6
119
1178
—
diazepam; oral, parenteral, rectal
N05BA01 [21604566]
5.8e-01
9.4e-01
—
—
—
—
—
cases:8.40%
controls:4.89%
cases:5.04%
controls:2.02%
—
—
—
—
—
—
—
—
—
—
10
58
109
1129
6
24
113
1163
—
—
—
—
—
zolmitriptan; nasal, oral
N02CC03 [21604378]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
0
6
119
1181
—
—
—
0
5
119
1179
—
ergotamine; inhalant, oral, parenteral, rectal, sublingual
N02CA02 [21604367]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
119
1180
—
—
—
—
—
—
indapamide; oral
C03BA11 [21601499]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
119
1177
—
—
—
—
—
—
Type 2 diabetes mellitus, with multiple complications
E11.7 [45561950]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
0
5
119
1153
prednisolone
S01BA04 [21603621]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.26%
—
—
—
—
—
—
—
—
—
—
—
—
0
15
119
1172
—
—
—
—
—
—
nedocromil; inhalant
R03BC03 [21603299]
1.1e+00
—
—
—
—
—
—
cases:5.04%
controls:1.68%
—
—
—
—
—
—
—
—
—
—
—
—
6
20
113
1167
—
—
—
—
—
—
cough suppressants and expectorants
R05FB02 [21603442]
4.8e-01
—
—
—
—
—
5.8e-02
cases:12.61%
controls:8.17%
—
—
—
—
—
—
—
—
—
—
cases:7.56%
controls:7.17%
15
97
104
1090
—
—
—
—
—
9
83
110
1075
SMOKING - SMOKE2: yes - SMOKE3: current - SMOKE5: current
SMOKING-1-1-1 [2002330115]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.35%
—
—
—
—
—
—
—
—
—
—
—
0
16
119
1171
—
—
—
—
—
hydrochlorothiazide; oral
C03AA03 [21601466]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
7.3e-01
cases:0.00%
controls:1.68%
cases:0.00%
controls:1.01%
—
—
—
—
—
—
cases:0.00%
controls:1.18%
cases:5.04%
controls:2.50%
0
20
119
1167
0
12
119
1175
—
—
—
0
14
119
1170
6
29
113
1129
alendronic acid; oral
M05BA04 [21604152]
—
—
—
—
—
—
6.2e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.04%
controls:2.76%
—
—
—
—
—
—
6
32
113
1126
metoprolol and thiazides
C07BB02 [21601710]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
6
119
1152
clindamycin, combinations
D10AF51 [21602309]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
0
5
119
1179
—
chlorhexidine
S03AA04 [21605193]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
0
7
119
1180
—
—
—
0
9
119
1175
—
methylprednisolone
D07AA01 [21602101]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
0
5
119
1153
hydrocortisone; oral, parenteral
H02AB09 [21602737]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.10%
cases:0.00%
controls:0.51%
—
—
—
—
—
—
cases:0.00%
controls:0.51%
cases:0.00%
controls:1.21%
0
13
119
1174
0
6
119
1181
—
—
—
0
6
119
1178
0
14
119
1144
meloxicam; oral, parenteral, rectal
M01AC06 [21603965]
—
—
—
—
—
—
1.1e-02
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.24%
controls:9.15%
—
—
—
—
—
—
11
106
108
1052
Diaphragmatic hernia without obstruction or gangrene
K44.9 [45533596]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
6
119
1152
Type 1 diabetes mellitus, Without complications
E10.9 [45581351]
-1.0e+50
-1.0e+50
-1.0e+50
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.68%
cases:0.00%
controls:1.85%
cases:0.00%
controls:0.42%
—
—
—
—
cases:0.00%
controls:1.86%
cases:0.00%
controls:2.76%
0
20
119
1167
0
22
119
1165
0
5
119
1182
—
—
0
22
119
1162
0
32
119
1126
triamterene; oral
C03DB02 [21601540]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
10
119
1148
Hypertrophy of breast
N62 [45577538]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
0
5
119
1153
Phakoemulsification with implantation of artificial lens in posterior chamber
CJE20 [2001301342]
-1.0e+50
—
—
—
—
—
2.3e-01
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
cases:4.20%
controls:3.37%
0
9
119
1178
—
—
—
—
—
5
39
114
1119
glimepiride; oral
A10BB12 [21600761]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
—
0
5
119
1182
—
—
—
—
—
citalopram; oral, parenteral
N06AB04 [21604712]
6.6e-01
—
—
—
-1.0e+50
—
6.8e-01
cases:7.56%
controls:4.04%
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
cases:10.08%
controls:5.35%
9
48
110
1139
—
—
—
0
8
119
1179
—
12
62
107
1096
antibiotics in combination with corticosteroids
D01AA20 [21601918]
1.2e+00
—
—
—
—
-1.0e+50
—
cases:5.04%
controls:1.60%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.44%
—
—
6
19
113
1168
—
—
—
—
0
17
119
1167
—
Thyroid insufficiency
104 [2001600104]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
0
9
119
1149
hydrocortisone and antiseptics
D07BA04 [21602146]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
0
7
119
1180
—
—
—
0
9
119
1175
—
SMOKING - SMOKE2: no - SMOKE3: never - SMOKE5: Unspecified
SMOKING-2-3-0 [2002330113]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:3.71%
cases:0.00%
controls:0.93%
—
—
—
—
—
—
—
—
—
—
0
44
119
1143
0
11
119
1176
—
—
—
—
—
hypromellose
S01KA02 [21605115]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.95%
—
—
—
—
—
—
0
11
119
1147
Peritonsillar abscess
J36 [45581858]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
0
5
119
1153
combinations of different antibiotics
S01AA30 [21603578]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
0
5
119
1179
—
Unstable angina
I20.00 [2000502384]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
0
5
119
1153
benzathine phenoxymethylpenicillin; oral
J01CE10 [21602850]
8.9e-02
—
—
—
—
—
6.7e-01
cases:14.29%
controls:13.23%
—
—
—
—
—
—
—
—
—
—
cases:11.76%
controls:6.39%
17
157
102
1030
—
—
—
—
—
14
74
105
1084
epitizide and potassium-sparing agents
C03EA03 [21601545]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
10
119
1148
metolazone and potassium-sparing agents
C03EA12 [21601550]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
10
119
1148
electrolytes with carbohydrates
B05BB02 [21601162]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.69%
—
—
—
—
—
—
0
8
119
1150
metformin; oral
A10BA02 [21600747]
—
—
-1.0e+50
—
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.93%
—
—
cases:0.00%
controls:1.35%
cases:0.00%
controls:3.97%
—
—
—
—
0
11
119
1176
—
0
16
119
1171
0
47
119
1137
—
Atherosclerosis of arteries of extremities
I70.2 [45538421]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
0
9
119
1149
Outcome of delivery
Z37 [45581024]
1.8e-02
-1.0e+50
—
—
—
-1.0e+50
—
cases:4.20%
controls:4.13%
cases:0.00%
controls:1.26%
—
—
—
—
—
—
cases:0.00%
controls:0.93%
—
—
5
49
114
1138
0
15
119
1172
—
—
—
0
11
119
1173
—
Fever, unspecified
R50.9 [45582716]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.20%
controls:0.60%
—
—
—
—
—
—
5
7
114
1151
Predominantly allergic asthma
J45.0 [45557624]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
119
1180
—
—
—
—
—
—
Ultrasound examination of uterus and parametria
LC2AE [2001306543]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.88%
controls:1.21%
—
—
—
—
—
—
7
14
112
1144
hydrocortisone and antiinfectives
S03CA04 [21605208]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
0
6
119
1178
—
cough suppressants and mucolytics
R05FB01 [21603441]
4.5e-01
—
—
—
—
—
7.1e-02
cases:11.76%
controls:7.83%
—
—
—
—
—
—
—
—
—
—
cases:7.56%
controls:7.08%
14
93
105
1094
—
—
—
—
—
9
82
110
1076
telithromycin; oral
J01FA15 [21602983]
—
—
—
—
—
—
1.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.20%
controls:1.55%
—
—
—
—
—
—
5
18
114
1140
terbinafine; oral
D01BA02 [21601967]
8.9e-01
-1.0e+50
—
—
—
—
7.0e-01
cases:4.20%
controls:1.77%
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
cases:5.88%
controls:3.02%
5
21
114
1166
0
5
119
1182
—
—
—
—
7
35
112
1123
lisinopril; oral
C09AA03 [21601787]
-1.0e+50
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
cases:0.00%
controls:2.02%
cases:0.00%
controls:1.26%
cases:0.00%
controls:0.51%
—
—
—
—
—
—
cases:0.00%
controls:1.21%
0
24
119
1163
0
15
119
1172
0
6
119
1181
—
—
—
0
14
119
1144
flumetasone and antiinfectives
S02CA02 [21605174]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
—
0
5
119
1182
—
—
—
—
—
Partial excision of meniscus of knee, arthroscopic
NGD05 [2001308109]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.20%
controls:1.47%
—
—
—
—
—
—
5
17
114
1141
Atherosclerotic heart disease
I25.1 [45596196]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.30%
—
—
—
—
—
—
0
15
119
1143
tibolone; oral
G03CX01 [21602536]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
0
5
119
1179
—
Pulmonary Disease
29 [38004472]
1.1e+00
1.3e+00
—
—
—
1.4e+00
6.2e-01
cases:6.72%
controls:2.36%
cases:6.72%
controls:1.94%
—
—
—
—
—
—
cases:6.72%
controls:1.77%
cases:10.08%
controls:5.70%
8
28
111
1159
8
23
111
1164
—
—
—
8
21
111
1163
12
66
107
1092
hydrocortisone; local oral
A01AC03 [21600036]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
0
6
119
1181
—
—
—
—
—
0
10
119
1148
short-acting sulfonamides - combinations
J01EB20 [21602943]
4.5e-01
—
—
—
—
—
7.1e-02
cases:11.76%
controls:7.83%
—
—
—
—
—
—
—
—
—
—
cases:7.56%
controls:7.08%
14
93
105
1094
—
—
—
—
—
9
82
110
1076
mefenamic acid; oral
M01AG01 [21603987]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
—
0
5
119
1182
—
—
—
—
—
Asthma, unspecified
J45.9 [45562456]
—
-1.0e+50
—
—
—
—
8.2e-01
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
cases:4.20%
controls:1.90%
—
0
7
119
1180
—
—
—
—
5
22
114
1136
salbutamol; inhalant
R03AC02 [21603256]
3.7e-01
1.2e+00
—
—
—
—
6.2e-01
cases:5.04%
controls:3.54%
cases:7.56%
controls:2.44%
—
—
—
—
—
—
—
—
cases:14.29%
controls:8.20%
6
42
113
1145
9
29
110
1158
—
—
—
—
17
95
102
1063
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
1.0e+00
—
—
—
—
—
8.1e-01
cases:9.24%
controls:3.54%
—
—
—
—
—
—
—
—
—
—
cases:10.92%
controls:5.18%
11
42
108
1145
—
—
—
—
—
13
60
106
1098
Acute subendocardial infarction unspecified coronary artery status
I21.49 [2000502437]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
0
5
119
1153
enalapril; oral, parenteral
C09AA02 [21601786]
3.3e-02
4.2e-01
—
—
—
2.5e-01
6.6e-02
cases:5.04%
controls:4.89%
cases:5.04%
controls:3.37%
—
—
—
—
—
—
cases:5.04%
controls:3.97%
cases:5.88%
controls:5.53%
6
58
113
1129
6
40
113
1147
—
—
—
6
47
113
1137
7
64
112
1094
SMOKING - SMOKE2: no - SMOKE3: former - SMOKE5: Unspecified
SMOKING-2-2-0 [2002330110]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
—
0
5
119
1182
—
—
—
—
—
progesterone; oral, parenteral, rectal, vaginal
G03DA04 [21602542]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
119
1178
—
—
—
—
—
—
triamcinolone
C05AA12 [40255458]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
0
5
119
1179
—
hyaluronic acid; parenteral
M09AX01 [21604179]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.20%
controls:1.38%
—
—
—
—
—
—
5
16
114
1142
Coeliac disease
K90.0 [45586745]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.69%
—
—
—
—
—
—
0
8
119
1150
cyproterone and estrogen
G03HB01 [21602617]
1.4e+00
—
—
—
—
—
1.3e+00
cases:6.72%
controls:1.77%
—
—
—
—
—
—
—
—
—
—
cases:5.04%
controls:1.47%
8
21
111
1166
—
—
—
—
—
6
17
113
1141
Pneumonia, unspecified
J18.9 [45601123]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
0
7
119
1177
—
diclofenac; oral, parenteral, rectal
M01AB05 [21603945]
5.9e-01
4.6e-01
—
—
—
5.3e-01
-1.4e-01
cases:22.69%
controls:13.98%
cases:8.40%
controls:5.48%
—
—
—
—
—
—
cases:9.24%
controls:5.66%
cases:12.61%
controls:14.25%
27
166
92
1021
10
65
109
1122
—
—
—
11
67
108
1117
15
165
104
993
enoxaparin; parenteral
B01AB05 [21600976]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
0
7
119
1151
Anterior colporraphy with sutures for primary cystocele
LEF00 [2001306704]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
0
5
119
1153
opium derivatives and expectorants
R05FA02 [21603439]
4.4e-01
—
—
—
—
—
3.2e-02
cases:12.61%
controls:8.51%
—
—
—
—
—
—
—
—
—
—
cases:7.56%
controls:7.34%
15
101
104
1086
—
—
—
—
—
9
85
110
1073
medroxyprogesterone; oral, parenteral
G03DA02 [21602540]
—
-1.0e+50
-1.0e+50
—
-1.0e+50
—
—
—
—
cases:0.00%
controls:2.36%
cases:0.00%
controls:0.76%
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
0
28
119
1159
0
9
119
1178
—
0
5
119
1182
—
—
fusidic acid; ointment
D06AX01 [21602062]
1.2e+00
-1.0e+50
—
—
—
—
—
cases:6.72%
controls:2.11%
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
8
25
111
1162
0
8
119
1179
—
—
—
—
—
cefuroxime; oral, parenteral
J01DC02 [21602884]
9.7e-01
—
—
—
—
—
—
cases:11.76%
controls:4.80%
—
—
—
—
—
—
—
—
—
—
—
—
14
57
105
1130
—
—
—
—
—
—
Postmenopausal bleeding
N95.0 [45567872]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.20%
controls:1.30%
—
—
—
—
—
—
5
15
114
1143
lorazepam; oral, parenteral, sublingual
N05BA06 [21604571]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.93%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
0
11
119
1176
—
—
—
—
0
5
119
1179
—
orphenadrine, combinations
M03BC51 [21604113]
6.6e-01
—
—
—
—
—
—
cases:5.88%
controls:3.12%
—
—
—
—
—
—
—
—
—
—
—
—
7
37
112
1150
—
—
—
—
—
—
Submucous leiomyoma of uterus
D25.0 [45542691]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.69%
—
—
—
—
—
—
0
8
119
1150
intermediate-acting sulfonamides - combinations
J01EC20 [21602948]
4.5e-01
—
—
—
—
—
7.1e-02
cases:11.76%
controls:7.83%
—
—
—
—
—
—
—
—
—
—
cases:7.56%
controls:7.08%
14
93
105
1094
—
—
—
—
—
9
82
110
1076
Chronic hypertension
205 [2001600203]
7.8e-01
—
—
—
—
-1.0e+50
—
cases:5.88%
controls:2.78%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.93%
—
—
7
33
112
1154
—
—
—
—
0
11
119
1173
—
Derangement of meniscus due to old tear or injury
M23.2 [45591779]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
0
5
119
1182
—
—
—
—
0
5
119
1179
—
Venereal disease screening
171128005 [4064905]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
0
5
119
1153
Malignant tumor of the upper outer quadrant of the mammary gland, ductal tumor
C50.41 [2000501002]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
0
6
119
1178
—
bupivacaine, combinations
N01BB51 [21604240]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.69%
—
—
—
—
—
—
0
8
119
1150
levomepromazine; oral, parenteral
N05AA02 [21604493]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.76%
cases:0.00%
controls:0.78%
—
—
—
—
—
0
9
119
1175
0
9
119
1149
insulin aspart; parenteral
A10AB05 [21600719]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.25%
—
—
—
—
—
—
0
26
119
1132
hyaluronic acid
S01KA01 [21605114]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.20%
controls:1.38%
—
—
—
—
—
—
5
16
114
1142
betamethasone
D07AC01 [21602120]
1.3e-01
—
—
—
—
—
—
cases:4.20%
controls:3.71%
—
—
—
—
—
—
—
—
—
—
—
—
5
44
114
1143
—
—
—
—
—
—
Examination and observation for other specified reasons
Z04.8 [45552063]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.20%
controls:0.43%
—
—
—
—
—
—
5
5
114
1153
Screening procedure
SPAT1324 [2001700425]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
0
5
119
1153
diclofenac
D11AX18 [21602355]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
0
6
119
1181
—
—
—
—
—
Laparoscopic hysterectomy
LCD04 [2001306586]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
0
5
119
1153
Hysteroscopic excision of lesion
LCB25 [2001306568]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
0
7
119
1151
trichlormethiazide; oral
C03AA06 [21601469]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
10
119
1148
fentanyl; nasal, sublingual, transdermal
N02AB03 [21604272]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
0
5
119
1153
False labour before 37 completed weeks of gestation
O47.0 [45582556]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
0
7
119
1151
roxithromycin; oral
J01FA06 [21602974]
6.9e-01
—
—
—
—
7.1e-01
7.5e-01
cases:16.81%
controls:9.18%
—
—
—
—
—
—
—
—
cases:5.04%
controls:2.53%
cases:17.65%
controls:9.15%
20
109
99
1078
—
—
—
—
6
30
113
1154
21
106
98
1052
hydrochlorothiazide and potassium-sparing agents
C03EA01 [21601543]
1.9e-01
5.8e-01
-1.0e+50
—
-1.0e+50
—
—
cases:8.40%
controls:7.08%
cases:6.72%
controls:3.88%
cases:0.00%
controls:0.93%
—
—
cases:0.00%
controls:0.67%
—
—
—
—
10
84
109
1103
8
46
111
1141
0
11
119
1176
—
0
8
119
1179
—
—
amlodipine; oral
C08CA01 [21601747]
—
-1.0e+50
—
—
—
—
-6.9e-02
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
—
—
cases:4.20%
controls:4.49%
—
0
10
119
1177
—
—
—
—
5
52
114
1106
mometasone; nasal
R01AD09 [21605051]
—
—
—
—
—
—
5.6e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:13.45%
controls:8.12%
—
—
—
—
—
—
16
94
103
1064
chlorphenamine, combinations
R06AB54 [21603468]
4.8e-01
—
—
—
—
—
5.8e-02
cases:12.61%
controls:8.17%
—
—
—
—
—
—
—
—
—
—
cases:7.56%
controls:7.17%
15
97
104
1090
—
—
—
—
—
9
83
110
1075
levodopa and decarboxylase inhibitor; oral
N04BA02 [21604465]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
6
119
1152
fusidic acid
D09AA02 [21602265]
1.2e+00
-1.0e+50
—
—
—
—
—
cases:6.72%
controls:2.11%
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
8
25
111
1162
0
8
119
1179
—
—
—
—
—
Fall into hole or other opening in surface
E883A [2000408881]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
119
1179
—
—
—
—
—
—
Cystoscopic balloon distension of bladder
KCV02 [2001305983]
—
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.20%
controls:0.00%
—
—
—
—
—
—
5
0
114
1158
miconazole
D01AC02 [21601921]
1.1e+00
—
—
—
—
—
1.3e+00
cases:7.56%
controls:2.78%
—
—
—
—
—
—
—
—
—
—
cases:4.20%
controls:1.12%
9
33
110
1154
—
—
—
—
—
5
13
114
1145
hydrocortisone
C05AA01 [21601608]
6.1e-01
—
—
—
—
—
-5.6e-02
cases:13.45%
controls:7.75%
—
—
—
—
—
—
—
—
—
—
cases:6.72%
controls:7.08%
16
92
103
1095
—
—
—
—
—
8
82
111
1076
Standard cardiac ultrasound examination
FM1AE [2001303278]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
0
9
119
1149
insulin lispro; parenteral
A10AB04 [21600718]
-1.0e+50
-1.0e+50
-1.0e+50
—
-1.0e+50
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.76%
cases:0.00%
controls:1.26%
cases:0.00%
controls:0.42%
—
—
cases:0.00%
controls:0.42%
cases:0.00%
controls:1.60%
cases:0.00%
controls:2.94%
0
9
119
1178
0
15
119
1172
0
5
119
1182
—
0
5
119
1182
0
19
119
1165
0
34
119
1124
Asthma
J45 [45596282]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.81%
—
—
—
—
—
—
0
21
119
1137
Diabetes mellitus in pregnancy: Pre-existing diabetes mellitus, insulin-dependent
O24.0 [45558213]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
0
5
119
1153
Chronic asthma and similar chronic obstructive pulmonary diseases
203 [2001600201]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.16%
—
—
—
—
—
—
0
25
119
1133
promethazine, combinations
R06AD52 [21603489]
4.8e-01
—
—
—
—
—
5.8e-02
cases:12.61%
controls:8.17%
—
—
—
—
—
—
—
—
—
—
cases:7.56%
controls:7.17%
15
97
104
1090
—
—
—
—
—
9
83
110
1075
furosemide; oral, parenteral
C03CA01 [21601518]
—
-1.0e+50
—
—
—
—
8.1e-02
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
cases:4.20%
controls:3.89%
—
0
14
119
1173
—
—
—
—
5
45
114
1113
cefadroxil; oral
J01DB05 [21602874]
5.9e-01
—
—
—
—
—
4.6e-01
cases:12.61%
controls:7.41%
—
—
—
—
—
—
—
—
—
—
cases:7.56%
controls:4.92%
15
88
104
1099
—
—
—
—
—
9
57
110
1101
dorzolamide
S01EC03 [21603695]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.42%
cases:0.00%
controls:0.67%
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
0
5
119
1182
0
8
119
1179
—
—
—
0
9
119
1175
—
Polyuria
R35 [45539331]
—
1.0e+50
—
—
—
—
—
—
—
cases:7.56%
controls:0.00%
—
—
—
—
—
—
—
—
—
—
—
9
0
110
1187
—
—
—
—
—
alprazolam; oral
N05BA12 [21604577]
1.2e+00
—
—
—
—
—
1.2e+00
cases:8.40%
controls:2.61%
—
—
—
—
—
—
—
—
—
—
cases:5.04%
controls:1.55%
10
31
109
1156
—
—
—
—
—
6
18
113
1140
calcipotriol; ointment
D05AX02 [21602039]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
—
0
5
119
1182
—
—
—
—
—
Unstable angina
I20.09 [2000502389]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.04%
—
—
—
—
—
—
0
12
119
1146
Hypersensitivity skin testing
268377001 [4147813]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
0
7
119
1151
insulin glargine; parenteral
A10AE04 [21600739]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.90%
—
—
—
—
—
—
0
22
119
1136
diclofenac
S01BC03 [21603641]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
0
5
119
1153
ebastine; oral
R06AX22 [21603521]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
—
—
—
—
—
0
12
119
1175
—
—
—
—
—
beclometasone; nasal
R01AD01 [21605043]
1.8e-01
—
—
—
—
—
—
cases:4.20%
controls:3.54%
—
—
—
—
—
—
—
—
—
—
—
—
5
42
114
1145
—
—
—
—
—
—
isosorbide mononitrate; oral
C01DA14 [21600324]
—
—
—
—
—
—
1.8e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.20%
controls:3.54%
—
—
—
—
—
—
5
41
114
1117
betahistine; oral
N07CA01 [21604833]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.12%
—
—
—
—
—
—
0
13
119
1145
atorvastatin; oral
C10AA05 [21601860]
—
-1.0e+50
—
—
-1.0e+50
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
0
10
119
1177
—
—
0
6
119
1181
—
—
clindamycin; oral, parenteral
J01FF01 [21602985]
—
-1.0e+50
—
—
—
—
8.1e-01
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
—
—
cases:6.72%
controls:3.11%
—
0
9
119
1178
—
—
—
—
8
36
111
1122
dipyridamole; oral, parenteral
B01AC07 [21600992]
-1.0e+50
-1.0e+50
—
—
-1.0e+50
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.43%
cases:0.00%
controls:1.01%
—
—
—
—
cases:0.00%
controls:0.42%
cases:0.00%
controls:1.27%
cases:0.00%
controls:1.90%
0
17
119
1170
0
12
119
1175
—
—
0
5
119
1182
0
15
119
1169
0
22
119
1136
clomifene; oral
G03GB02 [21602611]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
119
1182
—
—
—
—
—
—
temazepam; oral
N05CD07 [21604642]
5.6e-01
7.5e-01
—
—
—
—
9.6e-01
cases:6.72%
controls:3.96%
cases:4.20%
controls:2.02%
—
—
—
—
—
—
—
—
cases:7.56%
controls:3.02%
8
47
111
1140
5
24
114
1163
—
—
—
—
9
35
110
1123
Observation for suspected disease or condition, unspecified
Z03.9 [45552062]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
0
10
119
1148
Acute appendicitis, Without mention of peritonitis
5409X [2000404342]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
119
1182
—
—
—
—
—
—
Urgent procedure
ZXD05 [2001311386]
—
—
—
—
—
—
8.4e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.72%
controls:3.02%
—
—
—
—
—
—
8
35
111
1123
bisoprolol; oral
C07AB07 [21601689]
—
—
-1.0e+50
—
-1.0e+50
—
1.3e-01
—
—
—
—
cases:0.00%
controls:0.76%
—
—
cases:0.00%
controls:0.59%
—
—
cases:10.08%
controls:8.98%
—
—
0
9
119
1178
—
0
7
119
1180
—
12
104
107
1054
hydrocortisone buteprate
D07AB11 [21602115]
6.5e-01
—
—
—
—
—
-2.9e-02
cases:13.45%
controls:7.50%
—
—
—
—
—
—
—
—
—
—
cases:6.72%
controls:6.91%
16
89
103
1098
—
—
—
—
—
8
80
111
1078
erythromycin; oral, parenteral
J01FA01 [21602970]
1.2e+00
—
—
—
—
—
—
cases:10.08%
controls:3.20%
—
—
—
—
—
—
—
—
—
—
—
—
12
38
107
1149
—
—
—
—
—
—
Other intraoperative electrophysiological investigation in arhythmia or disturbance of impulse propagation
XFP96 [2001303143]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.04%
—
—
—
—
—
—
0
12
119
1146
dienestrol; oral, vaginal
G03CB01 [21602525]
1.9e+00
—
—
—
—
—
—
cases:5.04%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
—
6
9
113
1178
—
—
—
—
—
—
Extended examination of mouth
SAA03 [2001310276]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.69%
—
—
—
—
—
—
0
8
119
1150
Chronic superficial gastritis
K29.3 [45596316]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
0
5
119
1153
budesonide; inhalant
R03BA02 [21603285]
3.7e-01
5.3e-01
—
—
-1.0e+50
—
9.1e-01
cases:5.04%
controls:3.54%
cases:4.20%
controls:2.53%
—
—
—
—
cases:0.00%
controls:0.67%
—
—
cases:11.76%
controls:5.09%
6
42
113
1145
5
30
114
1157
—
—
0
8
119
1179
—
14
59
105
1099
clonazepam; oral, parenteral
N03AE01 [21604415]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.20%
controls:0.60%
—
—
—
—
—
—
5
7
114
1151
fluticasone; inhalant
R03BA05 [21603288]
—
9.9e-01
-1.0e+50
—
—
—
9.9e-01
—
—
cases:4.20%
controls:1.60%
cases:0.00%
controls:0.51%
—
—
—
—
—
—
cases:8.40%
controls:3.28%
—
5
19
114
1168
0
6
119
1181
—
—
—
10
38
109
1120
Endovascular dilatation of coronary arteries (PTCA)
FN1AT [2001303062]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
0
5
119
1153
fluticasone; nasal
R01AD08 [21605050]
8.0e-01
—
—
—
—
—
7.9e-01
cases:8.40%
controls:3.96%
—
—
—
—
—
—
—
—
—
—
cases:9.24%
controls:4.40%
10
47
109
1140
—
—
—
—
—
11
51
108
1107
metoprolol; oral, parenteral
C07AB02 [21601684]
2.3e-01
2.1e-01
—
—
—
—
-5.2e-03
cases:6.72%
controls:5.39%
cases:5.04%
controls:4.13%
—
—
—
—
—
—
—
—
cases:7.56%
controls:7.60%
8
64
111
1123
6
49
113
1138
—
—
—
—
9
88
110
1070
Right side
ZXA00 [2001311346]
-1.0e+50
—
—
—
—
—
1.0e+00
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
cases:5.88%
controls:2.25%
0
8
119
1179
—
—
—
—
—
7
26
112
1132
Cesarean section
8811 [2000101397]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
119
1182
—
—
—
—
—
—
podophyllotoxin
D06BB04 [21602086]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
119
1181
—
—
—
—
—
—
methotrexate
L01BA01 [21601423]
—
—
—
—
—
1.7e+00
1.1e+00
—
—
—
—
—
—
—
—
—
—
cases:4.20%
controls:0.76%
cases:4.20%
controls:1.47%
—
—
—
—
—
5
9
114
1175
5
17
114
1141
Heart failure, unspecified
I50.9 [45576879]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
6
119
1152
Left side
ZXA05 [2001311347]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.88%
controls:1.99%
—
—
—
—
—
—
7
23
112
1135
perphenazine; oral, parenteral, rectal
N05AB03 [21604502]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
0
8
119
1176
—
tamoxifen; oral
L02BA01 [21603831]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
6
119
1152
amoxicillin and beta-lactamase inhibitor; oral, parenteral
J01CR02 [21602863]
—
—
—
—
—
—
1.9e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.88%
controls:4.92%
—
—
—
—
—
—
7
57
112
1101
tetracycline; oral, parenteral
J01AA07 [21602805]
6.3e-01
—
—
—
—
1.9e+00
1.1e+00
cases:4.20%
controls:2.27%
—
—
—
—
—
—
—
—
cases:4.20%
controls:0.68%
cases:4.20%
controls:1.38%
5
27
114
1160
—
—
—
—
5
8
114
1176
5
16
114
1142
insulin lispro; parenteral
A10AC04 [21600726]
-1.0e+50
-1.0e+50
-1.0e+50
—
-1.0e+50
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.76%
cases:0.00%
controls:1.26%
cases:0.00%
controls:0.42%
—
—
cases:0.00%
controls:0.42%
cases:0.00%
controls:1.60%
cases:0.00%
controls:2.94%
0
9
119
1178
0
15
119
1172
0
5
119
1182
—
0
5
119
1182
0
19
119
1165
0
34
119
1124
nizatidine; oral, parenteral
A02BA04 [21600085]
1.2e+00
—
—
—
—
—
—
cases:9.24%
controls:2.95%
—
—
—
—
—
—
—
—
—
—
—
—
11
35
108
1152
—
—
—
—
—
—
phenylephrine, combinations
R01BA53 [21603214]
4.8e-01
—
—
—
—
—
5.8e-02
cases:12.61%
controls:8.17%
—
—
—
—
—
—
—
—
—
—
cases:7.56%
controls:7.17%
15
97
104
1090
—
—
—
—
—
9
83
110
1075
oxycodone; oral, parenteral
N02AA05 [21604260]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
0
5
119
1153
Menopausal and postmenopausal disorders, Postmenopausal bleeding
6271A [2000404940]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
119
1181
—
—
—
—
—
—
itraconazole; oral, parenteral
J02AC02 [21603081]
7.0e-01
1.5e+00
—
—
—
—
—
cases:6.72%
controls:3.45%
cases:4.20%
controls:1.01%
—
—
—
—
—
—
—
—
—
—
8
41
111
1146
5
12
114
1175
—
—
—
—
—
Antenatal screening for malformation
717800004 [36713462]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
0
5
119
1179
—
imidazoles/triazoles in combination with corticosteroids
D01AC20 [21601936]
1.1e+00
—
—
—
—
—
—
cases:8.40%
controls:2.86%
—
—
—
—
—
—
—
—
—
—
—
—
10
34
109
1153
—
—
—
—
—
—
terbutaline; oral, parenteral
R03CC03 [21603313]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
0
5
119
1182
—
—
—
—
—
0
5
119
1153
cefaclor; oral
J01DC04 [21602886]
8.0e-01
—
—
—
—
—
-1.0e+50
cases:4.20%
controls:1.94%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
5
23
114
1164
—
—
—
—
—
0
5
119
1153
piroxicam; oral, parenteral, rectal
M01AC01 [21603961]
6.2e-01
—
—
—
—
6.7e-01
2.1e-01
cases:24.37%
controls:14.83%
—
—
—
—
—
—
—
—
cases:4.20%
controls:2.20%
cases:9.24%
controls:7.60%
29
176
90
1011
—
—
—
—
5
26
114
1158
11
88
108
1070
dienestrol
G03CC02 [21602530]
1.9e+00
—
—
—
—
—
—
cases:5.04%
controls:0.76%
—
—
—
—
—
—
—
—
—
—
—
—
6
9
113
1178
—
—
—
—
—
—
fluocortolone
C05AA08 [21601612]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.59%
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
0
7
119
1180
0
8
119
1179
—
—
—
—
—
Dorsalgia, unspecified
M54.9 [45538791]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
0
9
119
1149
carbamazepine; oral, rectal
N03AF01 [21604417]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
0
7
119
1177
—
Tension-type headache
G44.2 [45581495]
—
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.88%
controls:1.12%
—
—
—
—
—
—
7
13
112
1145
methylprednisolone aceponate
D07AC14 [21602133]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
0
5
119
1153
Senile incipient cataract
H25.0 [45576699]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
0
5
119
1153
Single live birth
Z37.0 [45571346]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
0
9
119
1149
fluoxetine; oral
N06AB03 [21604711]
7.2e-01
—
—
—
—
-1.0e+50
9.2e-01
cases:5.04%
controls:2.53%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.93%
cases:5.04%
controls:2.07%
6
30
113
1157
—
—
—
—
0
11
119
1173
6
24
113
1134

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
23
92
2.86
4.36
5.1
6.0
—
—
—
0
0
63
409
2.14
4.04
5.1
3.6
—
—
—
0
0
22
91
2.74
3.91
3.7
2.6
0.21
1.61
e6/l
0.72
22
85
45
265
2.12
3.64
9.4
4.6
1.01
1.02
kg/l
0.69
34
171
12
34
3.80
3.31
1.6
2.8
—
—
—
0
0
57
381
1.94
3.16
6.7
3.5
30.76
227.52
e6/l
0.60
49
290
25
123
2.30
3.10
2.9
3.7
7.37
7.39
ph
0.67
16
79
15
59
2.76
2.91
4.1
1.7
—
—
—
0
0
37
219
2.00
2.87
6.1
4.3
575.63
163.25
ng/l
0.67
27
183
32
185
2.00
2.63
6.8
3.1
3.55
3.67
e6/l
0.03
20
88
31
178
2.00
2.59
1.9
3.2
0.83
0.80
mmol/l
0.68
31
161
49
329
1.83
2.56
5.9
3.4
0.23
0.50
e6/l
1.15
44
240
43
282
1.82
2.40
9.1
4.2
—
0.00
—
0
6
15
67
2.42
2.28
6.6
5.5
25.58
24.92
mmol/l
0.34
15
67
61
450
1.72
2.24
7.9
4.6
0.00
0.00
estimate
—
10
103
15
70
2.31
2.08
1.1
1.2
37.64
159.11
u/ml
—
7
30
54
393
1.68
2.03
2.9
2.2
111.90
201.37
u/l
1.12
49
369
76
609
1.68
1.95
8.7
4.5
0.00
0.00
estimate
-0.00
17
121
63
482
1.65
1.93
7.7
4.1
6.46
6.26
ph
0.74
40
270
7
24
3.03
1.75
1.4
2.4
77.34
54.08
%
—
7
24
47
343
1.61
1.69
9.6
4.4
0.00
0.00
estimate
-0.00
15
119
10
41
2.57
1.69
1.4
1.3
1.35
1.20
g/l
—
10
41
39
272
1.64
1.68
1.4
1.2
0.56
2.25
u/ml
1.09
11
71
74
603
1.59
1.66
8.6
4.5
0.00
0.00
estimate
-0.00
16
126
5
14
3.68
1.63
1.6
2.6
13.00
9.96
%
—
5
14
5
14
3.68
1.63
1.2
1.0
—
—
—
0
0
74
610
1.56
1.52
8.8
4.5
0.00
0.00
estimate
-0.00
17
131
55
425
1.54
1.51
3.0
3.5
2.39
2.36
mmol/l
0.88
50
390
56
435
1.54
1.50
9.1
4.3
436.53
105.32
e6/l
0.51
51
299
50
380
1.54
1.48
3.4
3.7
7.40
7.40
ph
0.06
39
272
9
40
2.35
1.43
1.4
1.3
0.25
0.23
g/l
—
9
40
45
338
1.53
1.39
5.8
6.6
—
—
—
0
0
12
61
2.07
1.38
1.4
1.4
—
—
—
0
0
14
76
1.95
1.36
1.8
2.6
1.24
1.21
%
0.05
14
76
33
234
1.57
1.30
6.5
4.9
—
—
—
0
0
59
476
1.47
1.26
11.6
11.8
0.00
0.00
e9/l
0.80
53
385
13
72
1.90
1.20
7.3
5.9
95.42
94.42
%
0.72
13
72
18
111
1.73
1.20
3.2
2.6
6.20
6.17
ph
—
10
78
13
75
1.82
1.08
1.8
2.6
0.53
0.63
%
0.58
13
75
45
354
1.43
1.06
1.6
1.7
21.30
21.91
nmol/l
0.09
38
297
5
22
2.33
1.04
1.0
1.6
—
—
—
0
0
10
54
1.93
1.00
1.8
1.6
4.66
9.07
iu/ml
—
5
15
7
36
2.00
0.99
1.0
1.2
—
—
—
0
0
62
522
1.39
0.98
13.0
14.9
1.35
1.24
inr
0.63
55
436
0
31
0.00
0.98
0.0
1.3
—
333.73
—
0
18
22
152
1.55
0.97
4.9
1.8
29.65
28.98
s
0.14
22
146
58
487
1.37
0.91
6.9
5.7
0.57
0.67
%
0.87
58
452
58
487
1.37
0.91
6.9
5.6
2.23
2.65
%
0.88
58
454
10
56
1.86
0.91
4.2
3.5
37.00
36.91
°c
—
10
56
6
29
2.12
0.90
1.0
1.8
6.18
6.50
pmol/l
—
6
29
69
597
1.37
0.89
6.3
5.8
1.22
1.22
mmol/l
0.03
61
513
29
217
1.44
0.88
1.6
1.3
16.83
41.16
iu/ml
—
6
76
31
235
1.43
0.88
1.5
1.4
2.03
2.45
g/l
0.61
18
134
58
490
1.36
0.87
6.9
5.7
7.73
8.72
%
2.25
58
462
22
156
1.50
0.87
1.4
1.2
—
—
—
0
0
21
149
1.50
0.83
1.5
1.4
286.67
585.64
titre
1.26
12
39
73
642
1.35
0.83
5.3
4.8
6.53
6.61
mmol/l
0.19
67
599
27
202
1.43
0.82
1.6
1.3
31.96
10.35
u/ml
0.34
12
78
53
445
1.34
0.81
6.9
4.4
33.33
36.14
ng/l
0.08
32
323
19
134
1.50
0.77
6.1
5.3
5.34
5.17
kpa
0.44
19
128
19
134
1.50
0.77
6.1
5.3
13.18
11.64
kpa
0.65
19
128
5
23
2.22
0.77
4.8
2.3
—
—
—
0
0
57
487
1.32
0.77
6.6
5.6
57.94
57.68
%
0.05
57
462
68
597
1.32
0.75
7.8
9.5
4.07
4.11
e9/l
0.05
62
528
58
498
1.32
0.75
6.9
5.7
27.89
27.48
%
0.09
58
472
12
76
1.64
0.75
3.0
3.6
—
—
—
0
0
11
68
1.68
0.74
1.2
1.6
—
—
—
0
0
38
308
1.34
0.73
3.9
4.0
—
—
—
0
0
19
137
1.46
0.70
2.8
4.0
1.04
1.09
mmol/l
0.45
19
119
28
352
0.73
0.70
3.4
3.4
—
—
—
0
0
19
138
1.45
0.68
1.2
1.2
—
—
—
0
0
5
29
1.75
0.64
4.8
2.6
47.00
61.86
%
—
5
29
18
131
1.44
0.64
6.4
5.4
7.44
7.42
ph
—
10
86
13
90
1.50
0.58
2.9
5.9
9.25
9.43
mmol/l
0.03
13
83
17
125
1.42
0.57
1.9
1.5
—
—
—
0
0
18
134
1.40
0.57
3.5
3.1
4.16
5.96
e9/l
0.50
18
118
9
62
1.49
0.54
1.9
3.4
24.34
24.97
mmol/l
—
9
62
41
349
1.27
0.54
6.6
5.3
—
—
—
0
0
89
830
1.28
0.52
6.5
4.8
15.03
14.90
pmol/l
0.20
84
745
51
449
1.24
0.50
2.1
2.1
—
—
—
0
0
12
86
1.44
0.46
1.3
1.4
—
—
—
0
0
9
126
0.69
0.46
6.2
2.7
1.42
1.89
%
—
9
118
5
31
1.64
0.43
1.0
1.1
—
—
—
0
0
8
57
1.43
0.43
1.6
1.2
—
—
—
0
0
23
278
0.79
0.42
1.4
1.4
—
—
—
0
0
0
15
0.00
0.41
0.0
1.2
—
—
—
0
0
0
15
0.00
0.41
0.0
1.0
—
—
—
0
0
0
16
0.00
0.41
0.0
1.8
—
—
—
0
0
40
350
1.21
0.40
2.8
3.7
2.25
6.97
mg/mmol
1.80
28
200
5
35
1.45
0.40
5.4
3.3
7.42
7.42
ph
—
5
35
6
89
0.66
0.34
12.8
2.9
58.50
74.28
e9/l
—
6
67
37
327
1.19
0.33
5.4
4.0
0.00
0.01
estimate
—
10
99
36
318
1.19
0.32
5.2
3.7
—
0.00
—
0
9
16
129
1.28
0.32
1.4
1.3
—
—
—
0
0
23
269
0.82
0.32
2.8
2.6
332.74
328.49
umol/l
0.05
23
234
56
515
1.16
0.31
2.5
2.1
112.09
98.30
pmol/l
0.91
20
248
8
110
0.71
0.30
1.0
1.4
—
—
—
0
0
95
984
0.83
0.28
7.1
6.2
2.61
2.66
mmol/l
0.22
90
906
8
63
1.29
0.28
1.4
1.7
—
—
—
0
0
87
831
1.17
0.28
27.2
21.2
13.76
13.81
%
0.11
87
821
38
342
1.16
0.27
2.7
3.1
9.46
39.24
mg/l
2.24
27
212
16
133
1.23
0.26
1.9
1.5
—
—
—
0
0
11
87
1.29
0.25
1.5
1.8
—
—
—
0
0
17
143
1.22
0.25
1.8
1.8
—
—
—
0
0
7
93
0.74
0.23
3.4
6.3
2.09
2.71
ug/l
—
7
84
13
107
1.24
0.22
1.2
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
16.36
—
0
10
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.4
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
7.35
—
0
13
0
14
0.00
0.20
0.0
1.6
—
—
—
0
0
5
69
0.71
0.17
1.0
1.3
—
—
—
0
0
15
131
1.17
0.15
1.3
1.6
—
—
—
0
0
99
1011
0.88
0.15
19.8
15.3
—
—
—
0
0
10
85
1.19
0.13
7.4
3.9
—
—
—
0
0
97
953
1.09
0.09
7.9
6.1
1.77
1.90
mu/l
0.56
91
879
17
155
1.11
0.09
1.9
1.9
—
—
—
0
0
33
348
0.93
0.09
2.1
2.1
—
—
—
0
0
47
485
0.95
0.06
3.0
2.7
—
—
estimate
—
0
0
101
1001
1.06
0.03
24.8
17.5
19.78
22.04
mg/l
0.44
92
822
10
92
1.09
0.03
1.3
1.1
—
—
—
0
0
25
242
1.04
0.02
1.7
1.8
462.65
470.15
pmol/l
0.04
20
197
5
59
0.84
0.00
1.0
1.4
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
3.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
215.71
—
0
7
0
5
0.00
-0.00
0.0
3.0
—
6.82
—
0
5
7
70
1.00
-0.00
1.0
1.3
—
37.70
—
0
5
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.4
—
1.19
—
0
5
0
5
0.00
-0.00
0.0
2.0
—
52.20
—
0
5
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.6
—
15.01
—
0
8
0
5
0.00
-0.00
0.0
5.0
—
38.60
—
0
5
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0

Mortality – FinRegistry

↥

This endpoint is excluded (not available in FinRegistry).

Relationships between endpoints

↥

Index endpoint: INTERSTITIAL_CYSTIT_CHRONIC – Interstitial cystitis (chronic), drug-induced

GWS hits: -

This endpoint is excluded (not available in FinRegistry).